Background: Patent ductus arteriosus (PDA) is a condition frequently found in very preterm infants, and its treatment remains a subject of debate. Furthermore, there are only a few studies available that have examined the impact of these treatments on the neurological outcome of the patient. Objective: To evaluate the neurodevelopmental outcome of PDA treatment on preterm infants born between 24+0 and 28+6 weeks of gestation. Methods: We conducted an observational multicentric cohort study (LIFT Cohort). We compared three groups of patients according to their PDA treatment strategy: medical treatment with ibuprofen, surgical ligation, and no treatment. The neurodevelopmental outcome was assessed with a physical examination and cognitive function evaluation at 2 years of age. A propensity score was used to reduce bias in the analysis. Results: Between 2003 and 2011, 857 infants (91.3%) were evaluated at 2 years of corrected age and included in the analysis: 248 received ibuprofen treatment (29%), 104 had PDA surgical ligation (12%), and 505 did not receive any PDA treatment (59%). Surgical ligation of PDA was significantly associated with neurodevelopmental impairment at 2 years of age (adjusted odds ratio = 2.2; 95% confidence interval: 1.4-3.4). Conclusion: We found an association between PDA surgical ligation and a nonoptimal neurodevelopmental outcome at 2 years of age for preterm infants born before 29 weeks of gestation. These results suggest that if surgical ligation is unavoidable, particular attention should be given to the patient's neurodevelopmental follow-up.

Keywords:
Preterm infant, Patent ductus arteriosus, Neurodevelopmental outcome
1.
Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR: Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1,000 grams or less. Pediatrics 2006;117:1113-1121.
2.
Narayanan M, Cooper B, Weiss H, Clyman RI: Prophylactic indomethacin: factors determining permanent ductus arteriosus closure. J Pediatr 2000;136:330-337.
3.
Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al: Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010;126:443-456.
4.
Kluckow M, Evans N: Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage. J Pediatr 2000;137:68-72.
5.
Gournay V: The ductus arteriosus: physiology, regulation, and functional and congenital anomalies. Arch Cardiovasc Dis 2011;104:578-585.
6.
Bancalari E, Claure N, Gonzalez A: Patent ductus arteriosus and respiratory outcome in premature infants. Biol Neonate 2005;88:192-201.
7.
Noori S, McCoy M, Friedlich P, Bright B, Gottipati V, Seri I, et al: Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 2009;123:e138-e144.
8.
Evans N: Preterm patent ductus arteriosus: a continuing conundrum for the neonatologist? Semin Fetal Neonatal Med 2015;20:272-277.
9.
Gudmundsdottir A, Johansson S, Håkansson S, Norman M, Källen K, Bonamy A-K: Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants. Neonatology 2015;107:87-92.
10.
Meyer S: Adequate timely treatment of patent ductus arteriosus in extremely low birth weight infants: an ongoing challenge. Neonatology 2015;107:256.
11.
Olsson KW, Sindelar R: Future benefits of sequential echocardiography: unmasking the indications for treatment of patent ductus arteriosus in extremely preterm infants. Neonatology 2015;108:99.
12.
McNamara PJ, Sehgal A: Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2008;93:F78.
13.
Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS: New intrauterine growth curves based on United States data. Pediatrics 2010;125:e214-e224.
14.
Flamant C, Branger B, Nguyen The Tich S, de la Rochebrochard E, Savagner C, Berlie I, et al: Parent-completed developmental screening in premature children: a valid tool for follow-up programs. PLoS One 2011;6: e20004.
15.
Weisz DE, More K, McNamara PJ, Shah PS: PDA ligation and health outcomes: a meta-analysis. Pediatrics 2014;133:e1024-e1046.
16.
Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A: Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr 2007;150:229-234.e1.
17.
Madan JC, Kendrick D, Hagadorn JI, Frantz ID; National Institute of Child Health and Human Development Neonatal Research Network: Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. Pediatrics 2009;123:674-681.
18.
Van Zanten SA, de Haan TR, Ursum J, van Sonderen L: Neurodevelopmental outcome of post-hemorrhagic ventricular dilatation at 12 and 24 months corrected age with high-threshold therapy. Eur J Paediatr Neurol 2011;15:487-492.
19.
Wang X, Xu Z, Miao C-H: Current clinical evidence on the effect of general anesthesia on neurodevelopment in children: an updated systematic review with meta-regression. PLoS One 2014;9:e85760.
20.
Favrais G, Tourneux P, Lopez E, Durrmeyer X, Gascoin G, Ramful D, et al: Impact of common treatments given in the perinatal period on the developing brain. Neonatology 2014;106:163-172.
21.
McPherson C, Grunau RE: Neonatal pain control and neurologic effects of anesthetics and sedatives in preterm infants. Clin Perinatol 2014;41:209-227.
22.
Jain A, Sahni M, El-Khuffash A, Khadawardi E, Sehgal A, McNamara PJ: Use of targeted neonatal echocardiography to prevent postoperative cardiorespiratory instability after patent ductus arteriosus ligation. J Pediatr 2012;160:584-589.e1.
23.
El-Khuffash AF, Jain A, McNamara PJ: Ligation of the patent ductus arteriosus in preterm infants: understanding the physiology. J Pediatr 2013;162:1100-1106.
24.
Harting MT, Blakely ML, Cox CS, Lantin-Hermoso R, Andrassy RJ, Lally KP: Acute hemodynamic decompensation following patent ductus arteriosus ligation in premature infants. J Invest Surg 2008;21:133-138.
25.
Jhaveri N, Moon-Grady A, Clyman RI: Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment. J Pediatr 2010;157:381-387.e1.
26.
Wickremasinghe AC, Rogers EE, Piecuch RE, Johnson BC, Golden S, Moon-Grady AJ, et al: Neurodevelopmental outcomes following two different treatment approaches (early ligation and selective ligation) for patent ductus arteriosus. J Pediatr 2012;161:1065-1072.
27.
McNamara PJ, Stewart L, Shivananda SP, Stephens D, Sehgal A: Patent ductus arteriosus ligation is associated with impaired left ventricular systolic performance in premature infants weighing less than 1,000 g. J Thorac Cardiovasc Surg 2010;140:150-157.
28.
Noori S, Friedlich P, Seri I, Wong P: Changes in myocardial function and hemodynamics after ligation of the ductus arteriosus in preterm infants. J Pediatr 2007;150:597-602.
29.
Ohlsson A, Shah PS: Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low-birth-weight infants. Cochrane Database Syst Rev 2015;3:CD010061.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.